Holen Sie sich die Stockscreener-App
3.30
0.61%
0.02
Vorhandelsmarkt:
3.34
0.04
+1.21%
Schlusskurs vom Vortag:
$3.28
Offen:
$3.32
24-Stunden-Volumen:
26,659
Relative Volume:
0.30
Marktkapitalisierung:
$82.43M
Einnahmen:
$1.79M
Nettoeinkommen (Verlust:
$-70.90M
KGV:
-0.2124
EPS:
-15.54
Netto-Cashflow:
$-34.95M
1W Leistung:
+4.10%
1M Leistung:
+13.01%
6M Leistung:
+52.07%
1J Leistung:
-15.38%
1-Tages-Spanne:
$3.12
$3.38
1-Wochen-Bereich:
$2.89
$3.4706
52-Wochen-Spanne:
$1.5201
$16.94
Senti Biosciences Inc Stock (SNTI) Company Profile
Firmenname
Senti Biosciences Inc
Sektor
Branche
Telefon
(650) 382-3281
Adresse
2 CORPORATE DRIVE, FIRST FLOOR, SOUTH SAN FRANCISCO
Vergleichen Sie SNTI mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SNTI
Senti Biosciences Inc
|
3.30 | 82.43M | 1.79M | -70.90M | -34.95M | -15.54 |
|
VRTX
Vertex Pharmaceuticals Inc
|
450.03 | 129.44B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.52 | 61.42B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
615.11 | 38.44B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
269.81 | 33.29B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
241.75 | 26.95B | 3.81B | -644.79M | -669.77M | -6.24 |
Senti Biosciences Inc Stock (SNTI) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2022-10-07 | Eingeleitet | Morgan Stanley | Equal-Weight |
Senti Biosciences Inc Aktie (SNTI) Neueste Nachrichten
Renaissance Technologies LLC Makes New $181,000 Investment in Senti Biosciences, Inc. (NASDAQ:SNTI) - Defense World
Senti Bio Reports First Quarter 2025 Financial Results and Provides a Corporate Update on Positive SENTI-202 Clinical Development - TradingView
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Senti Biosciences, Inc.SNTI - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Senti ... - Bluefield Daily Telegraph
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Senti Biosciences, Inc. - FinancialContent
Senti Biosciences’ (SNTI) Buy Rating Reiterated at Chardan Capital - Defense World
Senti Biosciences (SNTI) Maintains Buy Rating with Target Price Unchanged | SNTI Stock News - GuruFocus
Biotech Alert: Searches spiking for these stocks today - Yahoo Finance
SNTI: Senti Bio Shares Positive Phase 1 Trial Results for SENTI-202 | SNTI Stock News - GuruFocus
Senti Bio Releases Virtual Investor "What This Means” Segment - The Manila Times
Senti Biosciences Announces Positive Data for SENTI-202 in Phase 1 Trial at AACR Annual Meeting 2025 - Nasdaq
Breakthrough Leukemia Treatment: Senti Bio's CAR-NK Therapy Shows Promising Phase 1 Results at AACR 2025 - Stock Titan
Senti Bio to Present at the Citizens JMP Life Sciences Conference - The Manila Times
Breakthrough: Senti Bio's SENTI-202 Shows Promise in Treating Resistant Blood Cancer - Stock Titan
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Senti ... - Bluefield Daily Telegraph
Market Momentum Report: Prairie Operating Co (PROP)’s Positive Close at 4.10 - DWinneX
Closing Figures Unveiled: Senti Biosciences Inc (SNTI) Drop -27.20, Closes at 3.64 - DWinneX
An Analysis of Senti Biosciences Inc (SNTI)’s Potential Price Growth - knoxdaily.com
Senti Biosciences reports promising SENTI-202 trial results - Investing.com
SNTI’s Market Quandary: Decoding the Ups and Downs of 2023 - investchronicle.com
Senti Biosciences Pauses Enrollment in Hepatocellular Carcinoma Trial in China; Shares Fall - marketscreener.com
SNTI’s price-to-free cash flow ratio: What it means for investors - uspostnews.com
Senti Biosciences, Inc. Reports Additional Positive Preliminary Data from A Phase 1 Clinical Trial of SENTI-202 - marketscreener.com
Senti Bio's SENTI-202, A First-In-Class Off-The-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy, Demonstrates Positive Preliminary Clinical Results In The Treatment Of Patients With Relapsed/Refractory AML - marketscreener.com
Senti Biosciences Reports Positive Preliminary Data from Phase 1 Trial of SENTI-202 in Relapsed/Refractory AML at AACR Annual Meeting 2025 - Nasdaq
Breakthrough: Senti Bio's Novel Cell Therapy Achieves 71% Response Rate in Hard-to-Treat Blood Cancer - Stock Titan
Senti Biosciences to Showcase New Cell & Gene Therapy Data at AACR Annual Meeting 2025 - geneonline.com
Press Release Distribution & PR Platform - ACCESS Newswire
Senti Biosciences to Host Conference Call on SENTI-202 Phase 1 Clinical Data Ahead of AACR Annual Meeting - Nasdaq
New Cancer Treatment Data: Senti Bio's SENTI-202 Phase 1 Results Coming at AACR Conference - Stock Titan
Senti Bio Participates in a Virtual Investor KOL Connect Segment - The Manila Times
Senti Biosciences Releases KOL Segment Featuring Dr. Stephen Strickland on Advances in Acute Myeloid Leukemia Research - Nasdaq
Top Leukemia Experts Reveal Latest AML Treatment Breakthroughs: Senti Bio's SENTI-202 Program in Focus - Stock Titan
Senti Bio (NASDAQ: SNTI) to Participate in a Live Virtual Investor Closing Bell Segment - The Manila Times
Gene Circuit Pioneer Senti Bio Opens Access: CEO & CMO Host Live Investor Q&A - Stock Titan
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation into Senti Biosciences Inc. - ACCESS Newswire
Senti Bio appoints new scientific advisory board member By Investing.com - Investing.com South Africa
Senti Bio Bolsters Scientific Advisory Board with Appointment of James B. Trager, Ph.D. - Santé log
Senti Bio appoints new scientific advisory board member - Investing.com
Senti Bio Joins Webull Corporate Connect Service Platform - The Manila Times
Senti Biosciences joins Webull’s Corporate Connect Service By Investing.com - Investing.com Australia
Senti Biosciences joins Webull’s Corporate Connect Service - Investing.com
Clinical-Stage Biotech Senti Bio Launches New Investor Hub on Webull - Stock Titan
Senti Bio to Showcase SENTI-202 Clinical Data and Novel Logic Gated Gene Circuit Mechanism of Action in Oral and Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2025 - The Manila Times
Groundbreaking Clinical Trial Data: SENTI-202 Shows Promise for Hard-to-Treat Blood Cancer - Stock Titan
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation into Senti Biosciences Inc - ACCESS Newswire
Virtu Financial LLC Acquires Shares of 13,356 Senti Biosciences, Inc. (NASDAQ:SNTI) - Defense World
Senti Biosciences Files Shelf for 52.9 Million Shares - MarketScreener
Senti Biosciences Files For Shelf Of Up To 52.9 Mln Shares Of Common Stock By Selling StockholdersSEC Filing - Marketscreener.com
Senti Bio Reports Promising Trial Results and Financial Growth - TipRanks
Senti Biosciences Inc. (SNTI) reports earnings - Quartz
Finanzdaten der Senti Biosciences Inc-Aktie (SNTI)
Umsatz
Nettogewinn
Free Cashflow
ENV
5.24%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):